Home Daily Intelligence Tracker
    • Plans Blog Contact
    Axogen Inc logo
    AXGN

    Axogen Inc

    MaveScore 29 Low model confidence
    Last Price US$40.58 As of Jul 10, 2026
    Market Cap US$2.2b Company size context
    7D Performance -11.57% Past 7 days
    1Y Performance 236.48% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2026

    103 days old

    Market price date

    Jul 10, 2026

    2 days old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 29 Low confidence

    Stored data quality

    Freshness and coverage checks

    16/16 Current stored snapshot

    Quality

    13/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    6/25 Weak

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    0/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    10/15 Mixed

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    0/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Rewards durable profitability, margins, and positive free cash flow.
    • Favors positive earnings, positive cash flow, and lower multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Axogen Inc Overview

    Industry: Medical Devices

    Sector: Healthcare

    AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida. AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves withou Read More

    Axogen Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Axogen Inc

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Apr 28, 2026

    Quarterly result summary

    Revenue was $48.6M (reported). Net loss was -$19.6M. Net income was $4.1M.

    Revenue $48.6M reported
    Net loss -$19.6M reported
    Net income $4.1M reported
    Adjusted EBITDA $5.7M reported

    What changed

    • Revenue reported to $48.6M.

    Guidance / outlook

    We expect 2026 revenue growth to be at least 20%, or $270 million, for the full-year and gross margin to be in the range of 74% to 76%.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    Earnings material Earnings release Apr 28, 2026 SEC filing FORM 8-K Apr 28, 2026 SEC filing FORM 10-Q Apr 28, 2026 Earnings release Earnings release Feb 24, 2026 Earnings material Earnings release Feb 24, 2026 SEC filing FORM 10-K Feb 24, 2026 SEC filing FORM 8-K Feb 24, 2026 SEC filing FORM 8-K Jan 12, 2026 Earnings release Earnings release Jan 12, 2026 SEC filing FORM 10-Q Oct 29, 2025 Earnings release Earnings release Oct 29, 2025

    Recent News



    AxoGen stock price target raised to $28 from $22 at Leerink Partners
    9 minutes ago
    Citizens raises AxoGen stock price target to $34 on differentiated products
    4 minutes ago
    Axogen (AXGN): Valuation Perspective After Profitable Quarter and Raised 2025 Growth Guidance
    28 minutes ago

    Earnings Per Share

    Score 3.00/5
    Axogen Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Devices industry , Abbott Laboratories , DexCom Inc , Edwards Lifesciences Corp are companies with high ratings.

    Return on Equity

    Score 2.86/5
    Axogen Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Axogen Inc AXGN US$2.2b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 3.02/5
    Axogen Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Axogen Inc AXGN US$2.2b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Devices industry , Abbott Laboratories , DexCom Inc , Edwards Lifesciences Corp are companies with high ratings.

    Leverage

    Score 2.08/5
    Axogen Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Axogen Inc AXGN US$2.2b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Axogen Inc logo

    Axogen Inc

    US$40.58

    US$2.2b

    -11.57%

    236.48%